Legislation for trial registration and data transparency

被引:24
作者
Bian, Zhao-Xiang [1 ]
Wu, Tai-Xiang [2 ]
机构
[1] Hong Kong Baptist Univ, Sch Chinese Med, Hong Kong, Hong Kong, Peoples R China
[2] Sichuan Univ, W China Hosp, Chinese Evidence Based Med Ctr, Dept Clin Epidemiol, Chengdu 610041, Sichuan Prov, Peoples R China
关键词
OUTCOME REPORTING BIAS; CLINICAL-TRIALS; PUBLICATION BIAS; RANDOMIZED-TRIALS; EMPIRICAL-EVIDENCE; INFORMATION; STATEMENT; INDUSTRY;
D O I
10.1186/1745-6215-11-64
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Public confidence in clinical trials has been eroded by data suppression, misrepresentation and manipulation. Although various attempts have been made to achieve universal trial registration-e. g., Declaration of Helsinki, WHO clinical Trial Registry Platform (WHO ICTRP), the International Committee of Medical Journal Editors requirement-they have not succeeded, probably because they lack the enough power of enforcement. Legislation appears to be the most efficient and effective means to ensure that all researchers register their trials and disseminate their data accurately and in a timely manner. We propose that a global network be established. This could be accomplished in two steps. The first step is to legislate about trial registration and data transparency, such as USA's FDAAA Act 2007; and the second step to establish a global network to ensure uniform, international consistency in policy and enforcement of trial registration and data transparency.
引用
收藏
页数:4
相关论文
共 29 条